Efficacy of Sequential Therapy as the First-Line Treatment in the Eradication of Helicobacter pylori

被引:0
|
作者
Tamene, Yonas [1 ]
Mody, Shefali P. [2 ]
Sadiq, Kaiser O. [3 ]
Shivakumar, Yogamba M. [2 ]
Burra, Eshwar [4 ]
Shahid, Kamran [5 ]
Nath, Tuheen Sankar [6 ]
机构
[1] Calif Inst Behav Neurosci & Psychol, Internal Med, Fairfield, CA 94534 USA
[2] Calif Inst Behav Neurosci & Psychol, Med, Fairfield, CA USA
[3] Plexus Neuro & Stem Cell Res Ctr, Surg, Bangalore, India
[4] Govt Med Coll, Internal Med, Nizamabad, India
[5] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CA USA
[6] Calif Inst Behav Neurosci & Psychol, Clin Res, Fairfield, CA USA
关键词
h. pylori eradication; h; pylori; h. pylori infection; helicobacter pylori; h. pylori antibotic; 7-DAY TRIPLE THERAPY; TRIAL; CONCOMITANT; INFECTION; SUPERIOR; REGIMEN;
D O I
10.7759/cureus.45593
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Helicobacter pylori infection is a significant issue in global health as it is associated with a range of gastrointestinal disorders and an elevated likelihood of developing stomach cancer. The declining efficacy of standard triple therapy (TT) as the recommended treatment can be attributed to the emergence of drug resistant strains. Sequential therapy (ST) has been recognized as an alternative approach, wherein a combination of proton-pump inhibitor (PPI) and amoxicillin is administered for the initial five days, followed by a combination of PPI, clarithromycin, and metronidazole for the subsequent five days. In this comprehensive systematic review and meta-analysis, we have thoroughly assessed the effectiveness and tolerability of ST as a primary treatment option in comparison to TT for the eradication of H. pylori. The analysis comprised a total of 15 randomized controlled trials, encompassing a sample size of 5,219 patients. The collective findings indicate that ST exhibits promise as it achieves higher rates of eradication. Additionally, it is worth noting that this approach has the potential to yield cost savings and enhance treatment compliance when compared to TT. To summarize, this systematic review and meta-analysis provide evidence that ST is a viable option for the initial treatment of H. pylori eradication. It shows potential benefits compared to the standard TT, especially when there is resistance to clarithromycin. In order to establish ST as the preferred first-line treatment, it is imperative that additional research be conducted to address the aforementioned limitations and thoroughly investigate its long-term efficacy and safety profiles. Nevertheless, it is required that additional research be conducted in order to adequately tackle the constraints of the current studies and solidify its position as a favored treatment alternative. It is also essential to consider ST as a viable approach to improve the rates of H. pylori eradication. This method should be thoroughly examined in clinical practice to gain a deeper understanding of its effectiveness.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] THE TREND IN THE ERADICATION RATES OF FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION AND RISK FACTORS OF ERADICATION THERAPY
    Kim, S.
    Park, M.
    Park, S.
    Moon, W.
    Cheon, J.
    Kwon, H.
    Ku, K.
    Yoo, C.
    Kim, J.
    Lee, G.
    Song, S.
    Choi, Y.
    HELICOBACTER, 2013, 18 : 152 - 152
  • [42] The trend in helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Kwon, Hye Jung
    Choi, Youn Jung
    Kim, Jae Hyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 25 - 25
  • [43] Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for Helicobacter pylori Eradication
    Gisbert, Javier P.
    Fernandez Bermejo, Miguel
    Molina Infante, Javier
    Perez Gallardo, Belen
    Prieto Bermejo, Ana-Beatriz
    Matcos Rodriguez, Jose-Maria
    Roblcdo Andres, Pilar
    Gonzalez Garcia, Guadalupe
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (04) : 384 - 385
  • [44] The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori
    Uygun, A.
    Kadayifci, A.
    Safali, M.
    Ilgan, S.
    Bagci, S.
    HELICOBACTER, 2007, 12 (04) : 430 - 430
  • [45] The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori
    Uygun, Ahmet
    Kadayifci, Abdurrahman
    Safali, Mukerrem
    Ilgan, Seyfettin
    Bagci, Sait
    JOURNAL OF DIGESTIVE DISEASES, 2007, 8 (04) : 211 - 215
  • [46] Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for Helicobacter pylori Eradication in China
    Qian, Juan
    Ye, Feng
    Zhang, Jun
    Yang, Yan-Mei
    Tu, Hui-Ming
    Jiang, Qi
    Shang, Li
    Pan, Xiao-Lin
    Shi, Rui-Hua
    Zhang, Guo-Xin
    HELICOBACTER, 2012, 17 (06) : 478 - 485
  • [47] Optimizing first-line Helicobacter pylori eradication therapy: Prolonging treatment or add-on therapy, which is better?
    Leow, Alex Hwong-Ruey
    Azmi, Ahmad Najib
    Loke, Mun-Fai
    Vadivelu, Jamuna
    Goh, Khean Lee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 7 - 8
  • [49] Trend of First-Line and Second-Line Eradication Therapy for Helicobacter pylori Infection in Korea
    Chung, Jun-Won
    Jung, Hwoon-Yong
    Choi, Kee Don
    Song, Ho June
    Choi, Kwi-Sook
    Jung, Kee Wook
    Lee, Gin Hyug
    Kim, Do Hoon
    Kim, Jin-Ho
    GASTROENTEROLOGY, 2009, 136 (05) : A24 - A24
  • [50] First line therapy for Helicobacter pylori eradication in France
    Dupas, JL
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2003, 27 (03): : 467 - 472